Related references
Note: Only part of the references are listed.Phase II Open-Label Study of Anakinra in Intravenous Immunoglobulin-Resistant Kawasaki Disease
Isabelle Kone-Paut et al.
ARTHRITIS & RHEUMATOLOGY (2021)
Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open-Label, Randomized Study
Pierre Quartier et al.
ARTHRITIS & RHEUMATOLOGY (2021)
Severe Late-Onset Kawasaki Disease Successfully Treated With Anakinra
Gauthier Blonz et al.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2020)
The Presence of Uveitis Is Associated with a Sustained Response to the Interleukin (IL)-1 Inhibitors Anakinra and Canakinumab in Behcet's Disease
Claudia Fabiani et al.
OCULAR IMMUNOLOGY AND INFLAMMATION (2020)
Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International Registry of Anakinra for Pericarditis) study
Massimo Imazio et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2020)
Management of Behcet syndrome
Yusuf Yazici
CURRENT OPINION IN RHEUMATOLOGY (2020)
Systemic autoinflammatory diseases
Julie Krainer et al.
JOURNAL OF AUTOIMMUNITY (2020)
The long and winding road in pharmaceutical development of canakinumab from rare genetic autoinflammatory syndromes to myocardial infarction and cancer
Hermann Gram
PHARMACOLOGICAL RESEARCH (2020)
Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial
Claudia Kedor et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study
Hermine Brunner et al.
ARTHRITIS & RHEUMATOLOGY (2020)
Novel Pharmacotherapies for Recurrent Pericarditis: Current Options in 2020
Enrico Tombetti et al.
CURRENT CARDIOLOGY REPORTS (2020)
Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still's Disease
Antonio Vitale et al.
MEDIATORS OF INFLAMMATION (2020)
The reduction of concomitant glucocorticoids dosage following treatment with IL-1 receptor antagonist in adult onset Still's disease. A systematic review and meta-analysis of observational studies
Piero Ruscitti et al.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2020)
Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes
Antonio Vitale et al.
FRONTIERS IN MEDICINE (2020)
Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra
Lianne Kearsley-Fleet et al.
RHEUMATOLOGY (2019)
The right place of interleukin-1 inhibitors in the treatment of Behcet's syndrome: a systematic review
Alessandra Bettiol et al.
RHEUMATOLOGY INTERNATIONAL (2019)
Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors
Yang Yang et al.
CELL DEATH & DISEASE (2019)
Anaphylactic reaction to anakinra in a child with steroid-dependent idiopathic recurrent pericarditis and successful management with canakinumab
Serdar Epcacan et al.
CARDIOLOGY IN THE YOUNG (2019)
Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity
Alberto Mantovani et al.
IMMUNITY (2019)
Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response
Antonio Vitale et al.
FRONTIERS IN PHARMACOLOGY (2019)
The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation
Nathan Kelley et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Structural Basis of IL-1 Family Cytokine Signaling
James K. Fields et al.
FRONTIERS IN IMMUNOLOGY (2019)
The IL-1 family of cytokines and receptors in rheumatic diseases
Charles Anthony Dinarello
NATURE REVIEWS RHEUMATOLOGY (2019)
Anakinra Drug Retention Rate and Predictive Factors of Long-Term Response in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still Disease
Jurgen Sota et al.
FRONTIERS IN PHARMACOLOGY (2019)
Update on the management of colchicine resistant Familial Mediterranean Fever (FMF)
Georges El Hasbani et al.
ORPHANET JOURNAL OF RARE DISEASES (2019)
Anakinra in children and adults with Still's disease
Sebastiaan J. Vastert et al.
RHEUMATOLOGY (2019)
Use of Anakinra in Hospitalized Patients with Crystal-associated Arthritis
Jean W. Liew et al.
JOURNAL OF RHEUMATOLOGY (2019)
Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial
Carly A. Janssen et al.
RHEUMATOLOGY (2019)
Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis
Jurgen Sota et al.
FRONTIERS IN PHARMACOLOGY (2019)
Updated Treatment for Calcium Pyrophosphate Deposition Disease: An Insight
Shumaila M. Iqbal et al.
CUREUS JOURNAL OF MEDICAL SCIENCE (2019)
The family of the interleukin-1 receptors
Diana Boraschi et al.
IMMUNOLOGICAL REVIEWS (2018)
Overview of the IL-1 family in innate inflammation and acquired immunity
Charles A. Dinarello
IMMUNOLOGICAL REVIEWS (2018)
Efficacy of anakinra as a treatment for recurrent pericarditis
Sara Murias Loza et al.
ANALES DE PEDIATRIA (2018)
2018 update of the EULAR recommendations for the management of Behcet's syndrome
Gulen Hatemi et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease
Cem Gabay et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
The use of interleukin 1 receptor antagonist (anakinra) in Kawasaki disease: A retrospective cases series
Isabelle Kone-Paut et al.
AUTOIMMUNITY REVIEWS (2018)
Usefulness and safety of anakinra in refractory Kawasaki disease complicated by coronary artery aneurysm
Marie-Paule Guillaume et al.
CARDIOLOGY IN THE YOUNG (2018)
Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study
Jurgen Sota et al.
CLINICAL RHEUMATOLOGY (2018)
Tranilast directly targets NLRP3 to treat inflammasome-driven diseases
Yi Huang et al.
EMBO MOLECULAR MEDICINE (2018)
Bimodal Function of Anti-TNF Treatment: Shall We Be Concerned about Anti-TNF Treatment in Patients with Rheumatoid Arthritis and Heart Failure?
Przemyslaw J. Kotyla
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Use of Gevokizumab in Patients with Behcet's Disease Uveitis: An International, Randomized, Double-Masked, Placebo-Controlled Study and Open-Label Extension Study
Ilknur Tugal-Tutkun et al.
OCULAR IMMUNOLOGY AND INFLAMMATION (2018)
Mutations in osteoprotegerin account for the CCAL1 locus in calcium pyrophosphate deposition disease
C. J. Williams et al.
OSTEOARTHRITIS AND CARTILAGE (2018)
Systemic Juvenile Idiopathic Arthritis
Jennifer J. Y. Lee et al.
PEDIATRIC CLINICS OF NORTH AMERICA (2018)
Canakinumab for recurrent rheumatic disease associated-pericarditis: a case series with long-term follow-up
Nikolaos Kougkas et al.
RHEUMATOLOGY (2018)
Extracellular Neutrophil Proteases Are Efficient Regulators of IL-1, IL-33, and IL-36 Cytokine Activity but Poor Effectors of Microbial Killing
Danielle M. Clancy et al.
CELL REPORTS (2018)
A comprehensive review on adult onset Still's disease
Roberto Giacomelli et al.
JOURNAL OF AUTOIMMUNITY (2018)
Mechanisms, biomarkers and targets for adult-onset Still's disease
Eugen Feist et al.
NATURE REVIEWS RHEUMATOLOGY (2018)
Interleukin-33 is activated by allergen- and necrosis-associated proteolytic activities to regulate its alarmin activity during epithelial damage
Ian C. Scott et al.
SCIENTIFIC REPORTS (2018)
Anakinra Therapy for Non-cancer Inflammatory Diseases
Giulio Cavalli et al.
FRONTIERS IN PHARMACOLOGY (2018)
How Should We Classify Kawasaki Disease?
Edoardo Marrani et al.
FRONTIERS IN IMMUNOLOGY (2018)
A Review of Interleukin-1 in Heart Disease: Where Do We Stand Today?
Yishay Szekely et al.
CARDIOLOGY AND THERAPY (2018)
Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials
Nicolino Ruperto et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
2016 updated EULAR evidence-based recommendations for the management of gout
P. Richette et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Interleukin (IL)-1 inhibition with anakinra and canakinumab in Beh‡et's disease-related uveitis: a multicenter retrospective observational study
Claudia Fabiani et al.
CLINICAL RHEUMATOLOGY (2017)
Kawasaki disease: etiopathogenesis and novel treatment strategies
Shreya Agarwal et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2017)
Biologic drugs in adult onset Still's disease: a systematic review and meta-analysis of observational studies
Piero Ruscitti et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2017)
Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study
Karoline Krause et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment
Joachim R. Kalden et al.
NATURE REVIEWS RHEUMATOLOGY (2017)
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
P. M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans
Yukiko Kimura et al.
PEDIATRIC RHEUMATOLOGY (2017)
Juvenile Idiopathic Arthritis - Changing Times, Changing Terms, Changing Treatments
Susan Shenoi
PEDIATRICS IN REVIEW (2017)
Colchicine resistance and intolerance in familial mediterranean fever: Definition, causes, and alternative treatments
Seza Ozen et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2017)
Adult onset Still's disease-The evidence that anti-interleukin-1 treatment is effective and well-tolerated (a comprehensive literature review)
Guido Junge et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2017)
NF-kappa B signaling in inflammation
Ting Liu et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2017)
Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry
Gerd Horneff et al.
ARTHRITIS RESEARCH & THERAPY (2017)
The Therapeutic Role of Interleukin-1 Inhibition in Idiopathic Recurrent Pericarditis: Current Evidence and Future Challenges
George Lazaros et al.
FRONTIERS IN MEDICINE (2017)
Interleukin-1 and TRAF6-dependent activation of TAK1 in the absence of TAB2 and TAB3
Jiazhen Zhang et al.
BIOCHEMICAL JOURNAL (2017)
The genetics of gout: towards personalised medicine?
Nicola Dalbeth et al.
BMC MEDICINE (2017)
Treatment of mucocutaneous manifestations in Behcet's disease with anakinra: a pilot open-label study
Peter C. Grayson et al.
ARTHRITIS RESEARCH & THERAPY (2017)
Efficacy and safety profile of anti-interleukin-1 treatment in Behcet's disease: a multicenter retrospective study
Giacomo Emmi et al.
CLINICAL RHEUMATOLOGY (2016)
Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials
Simon Tarp et al.
RHEUMATOLOGY (2016)
Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab
Alexei A. Grom et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Systemic-onset juvenile idiopathic arthritis
Rolando Cimaz
AUTOIMMUNITY REVIEWS (2016)
A retrospective study of patients with adult-onset Still's disease: is pericarditis a possible predictor for biological disease-modifying anti-rheumatic drugs need?
Francesca Dall'Ara et al.
CLINICAL RHEUMATOLOGY (2016)
Adult-onset Still's disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients
Paolo Sfriso et al.
CLINICAL RHEUMATOLOGY (2016)
Critical Overview of the Risk Scoring Systems to Predict Non-Responsiveness to Intravenous Immunoglobulin in Kawasaki Syndrome
Donato Rigante et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence The AIRTRIP Randomized Clinical Trial
Antonio Brucato et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Recurrent pericarditis in children and adolescents: a multicentre cohort study
Massimo Imazio et al.
JOURNAL OF CARDIOVASCULAR MEDICINE (2016)
Diagnosis and Treatment of Systemic Juvenile Idiopathic Arthritis
Susan Shenoi et al.
JOURNAL OF PEDIATRICS (2016)
Interleukin 1α and the inflammatory process
Nelson C. Di Paolo et al.
NATURE IMMUNOLOGY (2016)
Calcium Pyrophosphate Deposition Disease
Ann K. Rosenthal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
SAPHO Syndrome: Current Developments and Approaches to Clinical Treatment
Davide Firinu et al.
CURRENT RHEUMATOLOGY REPORTS (2016)
Autoimmunity and autoinflammation as the yin and yang of idiopathic recurrent acute pericarditis
Luca Cantarini et al.
AUTOIMMUNITY REVIEWS (2015)
Kawasaki disease: a comprehensive review of treatment options
Rupal M. Patel et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2015)
Anakinra in Systemic Juvenile Idiopathic Arthritis: A Single-center Experience
Manuela Pardeo et al.
JOURNAL OF RHEUMATOLOGY (2015)
Efficacy of Anakinra in Refractory Adult-Onset Still's Disease Multicenter Study of 41 Patients and Literature Review
Francisco Ortiz-Sanjuan et al.
MEDICINE (2015)
Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey
Linda Rossi-Semerano et al.
ORPHANET JOURNAL OF RARE DISEASES (2015)
Gene-expression analysis of adult-onset Still's disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity
Nanguneri Nirmala et al.
PEDIATRIC RHEUMATOLOGY (2015)
Efficacy and safety of biological agents in adult-onset Still's disease
G. Cavalli et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2015)
Anakinra for the treatment of acute severe gout in critically ill patients
Jessica T. Thueringer et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2015)
Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent
A. Woerner et al.
RMD OPEN (2015)
Anakinra for the management of resistant idiopathic recurrent pericarditis. Initial experience in 10 adult cases
George Lazaros et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Inhibition of Interleukin-1 by Canakinumab as a Successful Mono-Drug Strategy for the Treatment of Refractory Behcet's Disease: A Case Series
Antonio Vitale et al.
DERMATOLOGY (2014)
Successful Treatment of Refractory Adult- Onset Still Disease With Canakinumab A Case Report
Simone Barsotti et al.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2014)
Canakinumab in a case of Adult onset Still's disease: Efficacy only on systemic manifestations
Alberto Lo Gullo et al.
JOINT BONE SPINE (2014)
Criteria for Behcet's disease with reflections on all disease criteria
Hasan Yazici et al.
JOURNAL OF AUTOIMMUNITY (2014)
Diagnosis and classification of Kawasaki disease
Judith Sanchez-Manubens et al.
JOURNAL OF AUTOIMMUNITY (2014)
Long-Term Efficacy of Interleukin-1 Receptor Antagonist (Anakinra) in Corticosteroid-Dependent and Colchicine-Resistant Recurrent Pericarditis
Martina Finetti et al.
JOURNAL OF PEDIATRICS (2014)
Rilonacept for Gout Flare Prevention in Patients Receiving Uric Acid-lowering Therapy: Results of RESURGE, a Phase III, International Safety Study
John S. Sundy et al.
JOURNAL OF RHEUMATOLOGY (2014)
The International Criteria for Behcet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria
F. Davatchi et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2014)
High dose anakinra for treatment of severe neonatal Kawasaki disease: a case report
Ashley Shafferman et al.
PEDIATRIC RHEUMATOLOGY (2014)
Effectiveness of First-Line Treatment With Recombinant Interleukin-1 Receptor Antagonist in Steroid-Naive Patients With New-Onset Systemic Juvenile Idiopathic Arthritis Results of a Prospective Cohort Study
Sebastiaan J. Vastert et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Is There a Window of Opportunity for Treatment of Systemic Juvenile Idiopathic Arthritis?
Peter A. Nigrovic
ARTHRITIS & RHEUMATOLOGY (2014)
Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis
Norman T. Ilowite et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Long-Term Safety and Efficacy of Rilonacept in Patients With Systemic Juvenile Idiopathic Arthritis
Daniel J. Lovell et al.
ARTHRITIS AND RHEUMATISM (2013)
The Interleukin-1 Family: Back to the Future
Cecilia Garlanda et al.
IMMUNITY (2013)
Reactive macrophage activation syndrome possibly triggered by canakinumab in a patient with adult-onset Still's disease
Christopher Banse et al.
JOINT BONE SPINE (2013)
The role of infection in Kawasaki syndrome
Nicola Principi et al.
JOURNAL OF INFECTION (2013)
Efficacy of an Interleukin-1β Receptor Antagonist (Anakinra) in Idiopathic Recurrent Pericarditis
Alessandra Scardapane et al.
PEDIATRIC CARDIOLOGY (2013)
Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial
Essack Mitha et al.
RHEUMATOLOGY (2013)
Apoptosome Structure, Assembly, and Procaspase Activation
Shujun Yuan et al.
STRUCTURE (2013)
Anakinra in Adult-Onset Still's Disease: Long-Term Treatment in Patients Resistant to Conventional Therapy
Cecilia Giampietro et al.
ARTHRITIS CARE & RESEARCH (2013)
Treatment of Acute Gouty Arthritis in Complex Hospitalized Patients With Anakinra
Pradipta Ghosh et al.
ARTHRITIS CARE & RESEARCH (2013)
Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases
Sebastien Ottaviani et al.
ARTHRITIS RESEARCH & THERAPY (2013)
Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator
Robert A. Terkeltaub et al.
ARTHRITIS RESEARCH & THERAPY (2013)
Drug survival and reasons for discontinuation of the first course of biological therapy in 301 juvenile idiopathic arthritis patients
M. Romano et al.
REUMATISMO (2013)
Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study
K. Krause et al.
ALLERGY (2012)
Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study
Ahmet Gul et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions
Naomi Schlesinger et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Canakinumab in a patient with juvenile Behcet's syndrome with refractory eye disease
Serdal Ugurlu et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
A child with severe relapsing Kawasaki disease rescued by IL-1 receptor blockade and extracorporeal membrane oxygenation
Sophie Cohen et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Successful treatment of adult patients with idiopathic recurrent pericarditis with an interleukin-1 receptor antagonist (anakinra)
Dimitrios Vassilopoulos et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2012)
Beneficial Effect of Interleukin 1 Inhibition with Anakinra in Adult-onset Still's Disease. An Open, Randomized, Multicenter Study
Dan Nordstrom et al.
JOURNAL OF RHEUMATOLOGY (2012)
Anakinra: A safe and effective first-line treatment in systemic onset juvenile idiopathic arthritis (SoJIA)
C. M. Hedrich et al.
RHEUMATOLOGY INTERNATIONAL (2012)
The Use of Canakinumab, a Novel IL-1β Long-Acting Inhibitor, in Refractory Adult-Onset Still's Disease
Apostolos Kontzias et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2012)
Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: Results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study
H. Ralph Schumacher et al.
ARTHRITIS CARE & RESEARCH (2012)
Treatment and management of pseudogout: insights for the clinician
Paul MacMullan et al.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2012)
A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)
Pierre Quartier et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study
Naomi Schlesinger et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Anakinra as First-Line Disease-Modifying Therapy in Systemic Juvenile Idiopathic Arthritis Report of Forty-Six Patients From an International Multicenter Series
Peter A. Nigrovic et al.
ARTHRITIS AND RHEUMATISM (2011)
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
Charles A. Dinarello
BLOOD (2011)
XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1 beta-mediated diseases
Alexander M. Owyang et al.
MABS (2011)
Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors
Armen Yuri Gasparyan et al.
RHEUMATOLOGY INTERNATIONAL (2011)
Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study
Katerina Laskari et al.
ARTHRITIS RESEARCH & THERAPY (2011)
Canakinumab for the Treatment of Acute Flares in Difficult-to-Treat Gouty Arthritis Results of a Multicenter, Phase II, Dose-Ranging Study
Alexander So et al.
ARTHRITIS AND RHEUMATISM (2010)
A Comprehensive Review of the Adverse Effects of Systemic Corticosteroids
David M. Poetker et al.
OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA (2010)
Anakinra's Efficacy is Variable in Refractory Gout: Report of Ten Cases
Kun Chen et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2010)
The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study
R. Terkeltaub et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Successful Treatment of Idiopathic Recurrent Pericarditis in Children With Interleukin-1 beta Receptor Antagonist (Anakinra) An Unrecognized Autoinflammatory Disease?
Paolo Picco et al.
ARTHRITIS AND RHEUMATISM (2009)
Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study
Norman Ilowite et al.
CLINICAL RHEUMATOLOGY (2009)
Resistant Behcet disease responsive to anakinra
Costantino Botsios et al.
ANNALS OF INTERNAL MEDICINE (2008)
EULAR recommendations for the management of Behcet disease
G. Hatemi et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis
Marco Gattorno et al.
ARTHRITIS AND RHEUMATISM (2008)
Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease:: preliminary experience in France
T. Lequerre et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
A pilot study of IL-1 inhibition by anakinra in acute gout
Alexander So et al.
ARTHRITIS RESEARCH & THERAPY (2007)
Diagnosis and management of adult onset Still's disease
P Efthimiou et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade
V Pascual et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
The precursor form of IL-1α is an intracrine proinflammatory activator of transcription
A Werman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
AP-1 subunits: quarrel and harmony among siblings
J Hess et al.
JOURNAL OF CELL SCIENCE (2004)
Share Paper
